Cardiac Troponin-I Concentration, Myocardial Arteriosclerosis, and Fibrosis in Dogs with Congestive Heart Failure because of Myxomatous Mitral Valve Disease

2013 ◽  
Vol 27 (3) ◽  
pp. 500-506 ◽  
Author(s):  
T. Falk ◽  
I. Ljungvall ◽  
N.E. Zois ◽  
K. Höglund ◽  
L.H. Olsen ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Mitral Valve ◽  
Mitral Valve Disease ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Cardiac Troponin I ◽  
Valve Disease

Serial measurements of cardiac troponin I in heart failure secondary to canine mitral valve disease

2019 ◽  
Vol 185 (11) ◽  
pp. 343-343 ◽  
Author(s):  
I-Ping Chan ◽  
San-Yu Wu ◽  
Chao-Chin Chang ◽  
Wen-Ying Chen
Keyword(s):  
Heart Failure ◽  
Mitral Valve ◽  
Medical Treatment ◽  
Mitral Valve Disease ◽  
Cardiac Troponin ◽  
Cardiac Death ◽  
Troponin I ◽  
Cardiac Troponin I ◽  
Valve Disease ◽  
Serial Measurements

Serial measurements of cardiac troponin I (cTnI) levels are considered to be better predictors of cardiac death than single-time-point analyses in human medicine. We hypothesised that cTnI levels could reflect the severity of myxomatous mitral valve disease (MMVD), and that serial changes in the cTnI level had a prognostic value in dogs with congestive heart failure (CHF) secondary to MMVD. Seventy-six dogs were initially enrolled and classified by the American College of Veterinary Internal Medicine (ACVIM) staging system. The single-timepoint cTnI concentration in these dogs significantly increased with the ACVIM stage. Twenty-seven dogs with CHF subsequently underwent serial measurement of cTnI levels, and the results showed that those who demonstrated a decrease in cTnI levels from the first to the third visit exhibited a higher risk of cardiac death than did those without such changes (P=0.012). We suspect that the downward trend in cTnI levels may be affected by medical treatment for CHF. In conclusion, although cTnI levels could reflect the severity of MMVD to a certain extent, the serial changes may be affected by medical treatment. Therefore, caution should be exercised when cTnI is used for assessment of the prognosis of CHF secondary to MMVD in dogs.

Cardiac Troponin I Is Associated with Severity of Myxomatous Mitral Valve Disease, Age, and C-Reactive Protein in Dogs

2010 ◽  
Vol 24 (1) ◽  
pp. 153-159 ◽  
Author(s):  
I. Ljungvall ◽  
K. Höglund ◽  
A. Tidholm ◽  
L.H. Olsen ◽  
M. Borgarelli ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Mitral Valve Disease ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Cardiac Troponin I ◽  
Valve Disease ◽  
C Reactive Protein ◽  
Reactive Protein

Biologic variability of cardiac troponin I in healthy dogs and dogs with different stages of myxomatous mitral valve disease using standard and high-sensitivity immunoassays

2017 ◽  
Vol 46 (2) ◽  
pp. 299-307 ◽  
Author(s):  
Randolph L. Winter ◽  
Ashley B. Saunders ◽  
Sonya G. Gordon ◽  
Matthew W. Miller ◽  
Geoffrey T. Fosgate ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Mitral Valve Disease ◽  
Cardiac Troponin ◽  
Troponin I ◽  
High Sensitivity ◽  
Cardiac Troponin I ◽  
Valve Disease ◽  
Healthy Dogs

Serial analysis of serum cardiac troponin I changes and correlation with clinical findings in 46 dogs with mitral valve disease

2014 ◽  
Vol 43 (2) ◽  
pp. 218-225 ◽  
Author(s):  
Zoe S. Polizopoulou ◽  
Christos K. Koutinas ◽  
Anastasia Dasopoulou ◽  
Michael Patsikas ◽  
Malcolm York ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Mitral Valve Disease ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Clinical Findings ◽  
Cardiac Troponin I ◽  
Valve Disease ◽  
Serum Cardiac Troponin

scholarly journals Blood lactate increases with the progression of mitral valve disease in dogs

2018 ◽  
Vol 38 (9) ◽  
pp. 1781-1786
Author(s):  
Jorge Cardoso Silva-Filho ◽  
Marlos G. Sousa ◽  
Evandro Zacché Pereira ◽  
Edna M.G. Ortiz ◽  
Rodrigo P. Franco ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Mitral Valve ◽  
Blood Lactate ◽  
Cardiac Remodeling ◽  
Mitral Valve Disease ◽  
Lactate Concentration ◽  
Tissue Perfusion ◽  
Valve Disease ◽  
Cross Sectional

ABSTRACT: In dogs with congestive heart failure, the upregulated sympathetic tone causes vasoconstriction that impairs peripheral blood supply, therefore causing the accumulation of lactate. In this prospective cross-sectional study with a longitudinal component, blood lactate was quantified in 10 healthy and 34 myxomatous mitral valve disease (MMVD) dogs to investigate its potential use as a diagnostic and prognostic biomarker. While there were no differences in lactate concentration between control animals and stages B1 (3.31±0.62mmol/L) and B2 (3.32±0.46mmol/L) dogs, significant differences were found between healthy (2.50±0.69mmol/L) and both C (3.99±0.47mmol/L) and D (6.97±1.23mmol/L) animals. When a cut-off of 3.35mmol/L was used, lactate was able to distinguish dogs with normal and remodeled hearts with a sensitivity of 78.2% and specificity of 63.6%. Also, significant correlations existed between lactate and indicators of cardiac remodeling. Finally, animals with blood lactate <3.5mmol/L carried a better prognosis when compared with dogs in which lactate was >5.0mmol/L. Our results suggest that the progression of MMVD results in accumulation of lactate within the bloodstream, which is likely attributable to the impaired peripheral tissue perfusion. In MMVD dogs, blood lactate may be used as a surrogate for cardiac remodeling, and an increased concentration is associated with a worse prognosis regarding the time to evolve into congestive heart failure.

Sign in / Sign up

Export Citation Format

Share Document